Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,077 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia Alzheimers Clear all
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIa L-serine Trial for eAD

NCT03062449
View directory record Official record
Conditions
Alzheimer Disease
Interventions
L-Serine, Placebo Gummy
Drug · Other
Lead sponsor
Aleksandra Stark
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

NCT03144921
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Memory Loss
Interventions
psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 25, 2026, 5:01 PM EDT
Not listed No phase listed Observational

On Site Sensors Monitoring Impacts of Cognitive Decline on ADLs

NCT04871698
View directory record Official record
Conditions
Dementia, Dementia Alzheimers
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 25, 2026, 5:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

NCT06129838
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C]-CS1P1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Terminated No phase listed Observational

Identifying Novel Aging Targets for Treatment of Delirium

NCT03682874
View directory record Official record
Conditions
Delirium, Dementia Alzheimers, Respiratory Failure
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 25, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

NCT00911690
View directory record Official record
Conditions
Dementia, Alzheimers Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
60 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

NCT01013610
View directory record Official record
Conditions
Mild Alzheimer's Disease
Interventions
LNK-754, Placebo
Drug
Lead sponsor
Link Medicine Corporation
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Sep 25, 2026, 5:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

NCT02221947
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 5:01 PM EDT
Withdrawn Phase 3 Interventional

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Baricitinib 4 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Completed No phase listed Observational

Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome

NCT02854917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

NCT00934050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005 (scyllo-inositol)
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 25, 2026, 5:01 PM EDT
Recruiting Not applicable Interventional

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

NCT03671889
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood Brain Barrier (BBB) Disruption
Device
Lead sponsor
InSightec
Industry
Eligibility
50 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
10
States / cities
Delray Beach, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT02245568
View directory record Official record
Conditions
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Interventions
LMTM
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Not listed
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Phoenix, Arizona • Fountain Valley, California • Laguna Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 3 Interventional

Multicenter Trial of Prednisone in Alzheimer's Disease

NCT00000178
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Prednisone
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Results available

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

NCT02593318
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 25, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening for Memory Studies

NCT01123018
View directory record Official record
Conditions
Memory Loss, Memory Deficits, Dementia, Alzheimer Disease
Interventions
Memtrax Memory screening test
Behavioral
Lead sponsor
John Wesson Ashford Jr
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Not applicable Interventional Results available

Caregiver Speaks: A Technologically Mediated Storytelling Intervention

NCT04103580
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Photo elicitation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 25, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
2,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 25, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
DHA (Docosahexaenoic Acid), Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 25, 2026, 5:01 PM EDT